Rheumatoid arthritis (RA) is the most common inflammatory arthropathy resulting in significant morbidity from pain and joint damage. 

Methotrexate, used as its treatment, contributes to significant side effects. 

Researchers from the Institute of Nano Science and Technology (INST) devised a new, cost-effective, safe drug delivery system.  

FDA-approved 9-aminoacridine (9AA) combined with Caffeic acid (CA) in a nano micelle formulation showed a marked reduction in the severity of rheumatoid arthritis by its enhanced anti-inflammatory effects on an experimental model. 

Human trials are pending before we have a potential solution in the future.